Update on the emerging role of telavancin in hospital-acquired infections

References

• Types of Healthcare-associated Infections [page on the Internet]AtlantaCenters for Disease Control and Preventionc2014 [updated March 26, 2014; cited December 1, 2014]Available from: http://www.cdc.gov/HAI/infectionTypes.htmlAccessed February 9, 2015
   Google Scholar
• LeuthnerKDCheungCMRybakMJComparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide nonsusceptible staphylococci and three vancomycin-resistant Staphylococcus aureusJ Antimicrob Chemother200658233834316787952
   PubMed Web of Science ®Google Scholar
• Barcia-MacayMLemaireSMingeot-LeclercqMPTulkensPMVan BambekeFEvaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate, and vancomycin-resistant Staphylococcus aureusJ Antimicrob Chemother20065861177118417062609
   PubMed Web of Science ®Google Scholar
• KrauseKMRenelliMDifuntorumSWuTXDebabovDVBentonBMIn vitro activity of telavancin against resistant gram-positive bacteriaAntimicrob Agents Chemother20085272647265218443122
   PubMed Web of Science ®Google Scholar
• JansenWTVerelAVerhoefJMilatovicDIn vitro activity of telavancin against grampositive clinical isolates recently obtained in EuropeAntimicrob Agents Chemother20075193420342417606689
   PubMed Web of Science ®Google Scholar
• PankeyGAAshcraftDSIn vitro synergy of telavancin and rifampin against Enterococcus faecium resistant to both linezolid and vancomycinOchsner J2013131616523532828
   PubMedGoogle Scholar
• MendesRESaderHSFarrellDJJonesRNWorldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continentsAntimicrob Agents Chemother20125673999400422508304
   PubMed Web of Science ®Google Scholar
• FarrellDJMendesRERhombergPRJonesRNRevised reference broth microdilution method for testing telavancin: effect on MIC results and correlation with other testing methodologiesAntimicrob Agents Chemother20145895547555125022579
   PubMed Web of Science ®Google Scholar
• MendesREFarrellDJSaderHSFlammRKJonesRNBaseline activity of telavancin against Gram-positive clinical isolates responsible for documented infections in US hospitals (2011–2012) as determined by the revised susceptibility testing methodAntimicrob Agents Chemother201559170270625348529
   PubMed Web of Science ®Google Scholar
• GoldsteinEJCitronDMMerriamCVWarrenYATyrrellKLFernandezHTIn vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium sppAntimicrob Agents Chemother20044862149215215155214
   PubMed Web of Science ®Google Scholar
• HigginsDLChangRDebabovDVTelavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureusAntimicrob Agents Chemother20054931127113415728913
   PubMed Web of Science ®Google Scholar
• HegdeSSReyesNWiensTPharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteriaAntimicrob Agents Chemother20044883043305015273119
   PubMed Web of Science ®Google Scholar
• ShawJPSeroogyJKaningaKHigginsDLKittMBarriereSPharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjectsAntimicrob Agents Chemother200549119520115616296
   PubMed Web of Science ®Google Scholar
• PlotkinPPatelKUminskiAMarzellaNTelavancin (vibativ), a new option for the treatment of gram-positive infectionsP T201136312713821572764
   PubMedGoogle Scholar
• RubinsteinELalaniTCoreyGRTelavancin vs vancomycin for hospital-acquired pneumonia due to gram-positive pathogensClin Infect Dis2011521314021148517
   PubMed Web of Science ®Google Scholar
• RubinsteinEStryjewskiMEBarrierreSLClinical utility of telavancin for treatment of hospital-acquired pneumonia: focus on non-ventilator-associated pneumoniaInfect Drug Resist2014712913524876786
   PubMed Web of Science ®Google Scholar
• StryjewskiMEBarrierreSLRubinsteinETelavancin vs vancomycin for bacteraemic hospitalized-acquired pneumoniaInt J Antimicrob Agents201342436736923891527
   PubMed Web of Science ®Google Scholar
• StryjewskiMEO’RiordanWDLauWKTelavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteriaClin Infect Dis200540111601160715889357
   PubMed Web of Science ®Google Scholar
• StryjewskiMEChuVHO’RiordanWDTelavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 studyAntimicrob Agents Chemother200650386286716495243
   PubMed Web of Science ®Google Scholar
• StryjewskiMEGrahamDRWilsonSETelavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organismsClin Infect Dis200846111683169318444791
   PubMed Web of Science ®Google Scholar
• WilsonSEO’RiordanWHopkinsAFriedlandHDBarriereSLKittMMATLAS investigatorsTelavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical proceduresAm J Surg2009197679179619095213
   PubMed Web of Science ®Google Scholar
• VIBATIV [package insert]South San Francisco, CATheravance, Inc 2013 Available from: www.vibativ.com Accessed August 7, 2014
   Google Scholar
• BarriereSLFarrellDJRhombergPRJonesRNSerum inhibitory and bactericidal activity of telavancin in non-infected subjects with severe renal impairment or end-stage renal diseaseDiagn Microbiol Infect Dis201480432732925306423
   PubMed Web of Science ®Google Scholar
• BarriereSLATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infectionsFuture Microbiol20105121765177321080861
   PubMed Web of Science ®Google Scholar
• LaPlanteKLMermelLAIn vitro activities of telavancin and vancomycin against biofilmproducing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strainsAntimicrob Agents Chemother20095373166316919451302
   PubMed Web of Science ®Google Scholar
• SmithKGemmellCGLangSTelavancin shows superior activity to vancomycin with multidrug-resistant Staphylococcus aureus in a range of in vitro biofilm modelsEur J Clin Microbiol Infect Dis201332101327133223624635
   PubMed Web of Science ®Google Scholar
• GanderSKinnairdAFinchRTelavancin: in vitro activity against staphylococci in a biofilm modelJ Antimicrob Chemother200556233734315972312
   PubMed Web of Science ®Google Scholar
• KaushalRHassounASuccessful treatment of methicillin-resistant Staphylococcus epidermidis prosthetic joint infection with telavancinJ Antimicrob Chemother20126782052205322544850
   PubMed Web of Science ®Google Scholar
• StryjewskiMELentnekAO’RiordanWA randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE studyBMC Infect Dis20141428924884578
   PubMed Web of Science ®Google Scholar
• NaceHLorberBSuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with telavancinJ Antimicrob Chemother20106561315131620375035
   PubMed Web of Science ®Google Scholar
• MarcosLACaminsBCSuccessful treatment of vancomycin-intermediate Staphylococcus aureus pacemaker lead infective endocarditis with telavancinAntimicrob Agents Chemother201054125376537820876369
   PubMed Web of Science ®Google Scholar
• JosonJGroverCDownerCPujarTHeidariASuccessful treatment of methicillinresistant Staphylococcus aureus mitral valve endocarditis with sequential linezolid and telavancin monotherapy following daptomycin failureJ Antimicrob Chemother20116692186218821653600
   PubMed Web of Science ®Google Scholar
• ChaftariAHachemRJordanMEvaluation of telavancin in the treatment of Grampositive bloodstream infections in cancer patientsPoster presented at: IDWeekOctober 8–12, 2014Philadelphia, PA
   Google Scholar
• CoreyGRRubinsteinEStryjewskiMEBassettiMBarriereSLPotential role for telavancin in bacteremic infections due to Gram-positive pathogens: focus on Staphylococcus aureusClin Infect Dis Epub1232014piiciu971
   Web of Science ®Google Scholar
• KenyanYRubinsteinETelavancin in the treatment of invasive Gram-positive infectionsClin Audit201242529
   Google Scholar
• PolyzosKAMavrosMNVardakasKZMakrisMCRafailidisPIFalagasMEEfficacy and safety of telavancin in clinical trials: a systematic review and meta-analysisPLoS One201278e4187022916113
   PubMed Web of Science ®Google Scholar
• CoreyGRKollefMHShorrAFTelavancin for hospital-acquired pneumonia: clinical response and 28-day survivalAntimicrob Agents Chemother20145842030203724419353
   PubMed Web of Science ®Google Scholar
• LaohavaleesonSBarriereSLNicolauDPKutiJLCost-effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin structure infectionsPharmacotherapy200828121471148219025428
   PubMed Web of Science ®Google Scholar